WO2011151418A8 - Nanosuspension formulation comprising a polydimethylsiloxane hydrophobic phase - Google Patents

Nanosuspension formulation comprising a polydimethylsiloxane hydrophobic phase Download PDF

Info

Publication number
WO2011151418A8
WO2011151418A8 PCT/EP2011/059149 EP2011059149W WO2011151418A8 WO 2011151418 A8 WO2011151418 A8 WO 2011151418A8 EP 2011059149 W EP2011059149 W EP 2011059149W WO 2011151418 A8 WO2011151418 A8 WO 2011151418A8
Authority
WO
WIPO (PCT)
Prior art keywords
nanosuspension formulation
hydrophobic phase
functional ingredient
nanosuspension
formulation
Prior art date
Application number
PCT/EP2011/059149
Other languages
French (fr)
Other versions
WO2011151418A3 (en
WO2011151418A2 (en
Inventor
Joerg Breitenbach
Didier R. Lefebvre
John M. Lipari
Original Assignee
Abbott Gmbh & Co. Kg
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg, Abbott Laboratories filed Critical Abbott Gmbh & Co. Kg
Publication of WO2011151418A2 publication Critical patent/WO2011151418A2/en
Publication of WO2011151418A8 publication Critical patent/WO2011151418A8/en
Publication of WO2011151418A3 publication Critical patent/WO2011151418A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A nanosuspension formulation comprising particles of at least one functional ingredient dispersed in a hydrophobic phase comprising a polydimethylsiloxane that can be used, e.g., in the pharmaceutical, cosmetics and food industry, in agriculture as well as for technical applications, and a method for producing said nanosuspension formulation are provided. The nanosuspension formulation of the invention can be highly concentrated, can be prepared also with poorly soluble functional ingredients and allows a gradual release of the functional ingredient into an aqueous environment which is accelerated compared to the dissolution of the functional ingredient when added as bulk material to the aqueous medium.
PCT/EP2011/059149 2010-06-02 2011-06-01 Nanosusupension formulation comprising a polydimethylsiloxane hydrophobic phase WO2011151418A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35067810P 2010-06-02 2010-06-02
US61/350,678 2010-06-02

Publications (3)

Publication Number Publication Date
WO2011151418A2 WO2011151418A2 (en) 2011-12-08
WO2011151418A8 true WO2011151418A8 (en) 2012-02-23
WO2011151418A3 WO2011151418A3 (en) 2012-06-28

Family

ID=44201068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/059149 WO2011151418A2 (en) 2010-06-02 2011-06-01 Nanosusupension formulation comprising a polydimethylsiloxane hydrophobic phase

Country Status (1)

Country Link
WO (1) WO2011151418A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018113280A (en) 2015-09-16 2019-10-16 ДиЭфБи СОРИА, ЭлЭлСи DELIVERY OF MEDICINE NANOPARTICLES AND METHODS OF USE THEREOF
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
US11497726B2 (en) 2018-03-16 2022-11-15 Dfb Soria, Ll. Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226905D0 (en) 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
DE4440337A1 (en) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate
JP3391802B2 (en) * 1996-05-30 2003-03-31 花王株式会社 Ultraviolet ray shielding fine particles, method for producing the same and cosmetics
DE19932157A1 (en) * 1999-07-13 2001-01-18 Pharmasol Gmbh Process for the gentle production of ultra-fine microparticles and nanoparticles
DE102004039212A1 (en) * 2004-08-12 2006-03-02 Wacker-Chemie Gmbh Rheology control of Pickering emulsion by electrolytes
GB0724226D0 (en) * 2007-12-12 2008-01-23 Univ Liverpool Composition for the treatment of a detached retina and method of production thereof

Also Published As

Publication number Publication date
WO2011151418A3 (en) 2012-06-28
WO2011151418A2 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
WO2011116963A3 (en) Lipid nanoparticle capsules
WO2008013785A3 (en) Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
EP3679924A3 (en) Formulation comprising particles
MX2011013726A (en) Nanodispersion of a drug and process for its preparation.
WO2011131947A3 (en) A process for particle processing of active pharmaceutical ingredients
SG196810A1 (en) Controlled release pharmaceutical or foodformulation and process for its preparation
WO2014044461A3 (en) Stabilization of capsule systems in laundry detergents and other cleaning products
MX362637B (en) Emulsifier system.
WO2012158483A3 (en) Adhesive containing microparticles
BR112014033005A2 (en) confectionery product comprising agglomerated oily powder
BR112013000675A2 (en) nanoparticle, process for producing a nanoparticle comprising a zein matrix and a basic amino acid, process for producing a nanoparticle comprising a zein matrix, and a basic amino acid and a fat-soluble biologically active compound, composition and food product
IL224430B (en) Liquid pharmaceutical formulation comprising st-246 and a beta-cyclodextrin, a process of making the liquid formulation, a unit dosage liquid formulation and a process for preparing a water-soluble solid st-246 pharmaceutical formulation
WO2011128623A3 (en) Improvements relating to antiviral compositions
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2015085070A3 (en) Liquid-fertilized ready formulations of bifenthrin
WO2010117199A3 (en) Coenzyme q10 nanoparticles, preparation method thereof and composition containing said nanoparticles
PH12014502191A1 (en) Capsule disintegrable in large-intestine-specific manner
WO2017037075A8 (en) Composition containing echinacea extract and linoleic acid derivatives
BR112015029773A2 (en) aroma coated powders
WO2013182518A3 (en) Particulate composition for food products comprising an emulsifier
WO2014130553A3 (en) Tablet dosage form comprising ritonavir and lopinavir
EP4233896A3 (en) Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
WO2011151418A3 (en) Nanosuspension formulation comprising a polydimethylsiloxane hydrophobic phase
EP3651733A4 (en) Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof
WO2009028598A1 (en) Sustained release preparation and process for production thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11724608

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11724608

Country of ref document: EP

Kind code of ref document: A2